Amrutanjan Reports Q2 Revenue of ₹1.35 Billion Versus ₹1.18 Billion YoY

Market snapshot: Amrutanjan Health Care Limited announced its Q2 financial results, delivering top-line expansion with revenue of ₹1.35 billion (₹135 crore) compared to ₹1.18 billion (₹118 crore) in the prior year period. The performance underscores steady momentum in core over-the-counter health categories.

Data Snapshot

• Q2 Revenue reached ₹1.35 billion (₹135 crore) compared to ₹1.18 billion (₹118 crore) in Q2 of the previous year.
• Year-on-year revenue expansion stands at ≈14.41% (derived: ₹1.35B vs ₹1.18B).

What's Changed

• Q2 top-line increased by ₹170 million (₹17 crore) over the previous year period, moving from ₹1.18 billion to ₹1.35 billion.

Key Takeaways

• Revenue expanded ≈14.41% YoY in Q2, driven by core pain management product lines.
• Top-line scale reached ₹1.35 billion (₹135 crore) compared to ₹1.18 billion (₹118 crore) in Q2 of the previous fiscal year.

SAHI Perspective

Amrutanjan's top-line trajectory demonstrates double-digit revenue growth in the quarter. Maintaining product velocity while executing on sales reach remains a pivotal driver for earnings sustainability.

Market Implications

Steady revenue expansion signals health in consumer OTC categories, positioning the company well against broader FMCG volume recovery trends.

Trading Signals

Market Bias: Bullish

Q2 revenue expanded to ₹1.35 billion (₹135 crore) from ₹1.18 billion (₹118 crore) YoY, reflecting top-line growth of ≈14.41% supported by core product demand.

Overweight: OTC Healthcare, FMCG

Trigger Factors:

• Sustained volume growth in pain management balms
• Execution of retail chemist network expansion targets

Time Horizon: Near-term (0-3 months)

Industry Context

The OTC pain management and healthcare market relies heavily on distribution depth and brand recall, where established category leaders benefit from steady household penetration.

Key Risks to Watch

• Raw material cost pressures impacting operational margins
• Competitive intensity in regional OTC and feminine hygiene segments

Recent Developments

Amrutanjan Health Care announced plans to establish 100,000 direct chemist outlets in FY27 to expand retail distribution depth and market penetration.

Closing Insight

Consistent revenue expansion highlights Amrutanjan's brand strength; continued focus on distribution execution will determine forward operating leverage.

High Performance Trading with SAHI.